Loading
HKSEHealthcareBiotechnology
Latest quote
HK$26.10
−HK$0.22 · -0.84%
Shaanxi Mycotech Pharmaceutical Technology Co., Ltd. operates as a platform-based biotechnology company dedicated to accelerating the global innovation and development of next-generation bi-multi-specific peptide drugs. Its products include MT1013, which is a dual-targeting receptor agonist polypeptide that simultaneously targets the CaSR and the OGP receptor. It is designed for the treatment of SHPT, CKD-MBD with Osteoporosis and SHPT not on Dialysis. The company was founded by Wang Bing on January 19, 2007 and is headquartered in Xi'an, China.
Latest quote
HK$26.10
−HK$0.22 · -0.84%
Regular session · HKT · Market data may be delayed.
Shaanxi Mycotech Pharmaceutical Technology Co., Ltd. operates as a platform-based biotechnology company dedicated to accelerating the global innovation and development of next-generation bi-multi-specific peptide drugs. Its products include MT1013, which is a dual-targeting receptor agonist polypeptide that simultaneously targets the CaSR and the OGP receptor. It is designed for the treatment of SHPT, CKD-MBD with Osteoporosis and SHPT not on Dialysis. The company was founded by Wang Bing on January 19, 2007 and is headquartered in Xi'an, China.
Day range
Current HK$26.10
52-week range
Current HK$26.10
Regular session · HKT · Market data may be delayed.
Shaanxi Mycotech Pharmaceutical Technology Co., Ltd. operates as a platform-based biotechnology company dedicated to accelerating the global innovation and development of next-generation bi-multi-specific peptide drugs. Its products include MT1013, which is a dual-targeting receptor agonist polypeptide that simultaneously targets the CaSR and the OGP receptor. It is designed for the treatment of SHPT, CKD-MBD with Osteoporosis and SHPT not on Dialysis. The company was founded by Wang Bing on January 19, 2007 and is headquartered in Xi'an, China.
Day range
Current HK$26.10
52-week range
Current HK$26.10
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
